“We will use optical genome mapping for molecular diagnosis of brain tumors, which is a new application of this technology specifically designed to detect structural variants, meaning large chan...
For people taking popular blood thinners rivaroxaban (brand name Xarelto) and apixaban (brand name Eliquis) after having a blood clot, a reduced dose may limit the future risk of bleeding as well as hospital visits, a Michigan Medicine-led study suggests.
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back.
If your child has cancer symptoms or a confirmed diagnosis, you’re likely looking for a pediatric oncologist. And nothing but the best will do.This is precisely what you’ll find at the Cancer and Blood Disease Institute at Children’s Hospital Los Angeles. CHLA has been at the forefront of pediatric cancer care and research for decades.
Huntsman Cancer Institute joins other institutions through myeloMATCH, a program that matches patients with clinical trials that specifically target their disease.
Coping with grief and holiday sadness; "biological age" as a tool to predict early colorectal cancer, genetic mutations accumulate in smokers with MDS, two clinical trials show promise for an antibody to treat high-risk form of lymphoma, and more.
Washington University School of Medicine in St. Louis has received a renewal of a prestigious research grant from the National Cancer Institute. Led by principal investigator, Daniel Link, MD, the Specialized Program of Research Excellence (SPORE) grant in leukemia provides funding for translational research.
Huntsman Cancer Institute researchers have identified a gene variant found in a high-altitude Andean population that may predict severity of diseases and responses to treatments for patients with certain types of blood cancer.
Stephen D. Nimer, M.D., has been awarded the American Society of Hematology’s Mentor Award for 2024. As director of Sylvester Comprehensive Cancer Center, Nimer lifts up and guides other researchers to create a collaborative environment that drives scientific discovery and quality patient care.
The NCCN Oncology Research Program (ORP) announces funding of a project that will underpin innovative research on optimal management of side effects secondary to treatment with poly ADP ribose polymerase inhibitors (PARPi).
A new review in Blood Cancer Discovery outlines a key regulatory decision by an FDA committee that greenlights a new biomarker endpoint for accelerated drug approval in multiple myeloma and could cut a decade off the drug development process.
A new treatment is showing promise for people with high-risk smoldering multiple myeloma (SMM). This precancerous condition can progress to active multiple myeloma, a type of blood cancer. High-risk SMM carries a higher likelihood of progression.
Three clinical trials led by researchers from The University of Texas MD Anderson Cancer Center demonstrated significant positive results from novel triplet therapies in the treatment of relapsed or refractory and newly diagnosed leukemias. The results were presented at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition. More information on all ASH Annual Meeting content from MD Anderson can be found at MDAnderson.org/ASH.
About a third of patients with diffuse large B cell lymphoma (DLBCL), a fast-growing form of lymphoma, will see their disease advance or recur following treatment. Seeking a new treatment strategy that might boost the effectiveness of existing DLBCL therapies, a team from Roswell Park has been working to understand the underlying mechanisms of the targeted chemotherapy venetoclax. Their findings, to be presented during a talk today at the 66th annual meeting of the American Society of Hematology (ASH) in San Diego, California, provide strong preclinical evidence that adding venetoclax to standard treatment may improve outcomes in patients with treatment-resistant B-cell lymphomas.
Researchers from Roswell Park Comprehensive Cancer Center will present compelling findings showcasing significant benefits of resistance training for patients with multiple myeloma, in a talk at the 66th American Society of Hematology (ASH) Annual Meeting. The study, led by Jens Hillengass, MD, PhD, and Janine Joseph, MS, MBA, presents new evidence documenting that targeted exercise regimens can alleviate fatigue, improve sleep and reduce pain, offering new hope for enhancing quality of life in cancer care.
ASH 2024 Presentations: Two clinical trials testing the antibody loncastuximab tesirine (Zynlonta) showed encouraging results in patients with high-risk forms of two blood cancers – follicular lymphoma and marginal zone lymphoma.
Patients with acute myeloid leukemia who have lower education levels and lower income are less likely to receive a allogeneic hematopoietic stem cell transplant for acute myeloid, however, if they can access the treatment, are equally likely to benefit from transplant as patients with more education and higher income, according to a new study from Fred Hutch Cancer Center presented at the annual meeting of the American Society of Hematology.
Researchers at Children’s Hospital of Philadelphia (CHOP) and the Children’s Oncology Group (COG) announced the results of a Phase 3 study that demonstrated adding the bi-specific T-cell engager, blinatumomab, to chemotherapy for newly diagnosed National Cancer Institute (NCI) standard risk (SR) B-cell acute lymphoblastic leukemia (B-ALL) pediatric patients significantly improves survival outcomes. The results were published today in the New England Journal of Medicine and will be presented during the plenary session at the 66th American Society of Hematology (ASH) Annual Meeting & Exposition in San Diego on December 8.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right
